Evidence map›Paper›PMID 22403058›Full record

ArticleInternational journal of hematology2012

Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).

Nozomu Kawashima, Akira Shimada, Takeshi Taketani, Yasuhide Hayashi, Nao Yoshida, Kimikazu Matsumoto, Yoshiyuki Takahashi, Seiji Kojima, Koji Kato

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. 3q26.2/Cancers · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nozomu KawashimaDivision of Hematology/Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, 453-8511, Japan. kwnozomu@med.nagoya-u.ac.jp
Akira Shimada
Takeshi Taketani
Yasuhide Hayashi
Nao Yoshida
Kimikazu Matsumoto
Yoshiyuki Takahashi
Seiji Kojima
Koji Kato
Japanese Red Cross Nagoya Daiichi Hospital · JPNagoya University · JPGunma Children's Medical Center · JPShimane University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia with abnormal bone marrow eosinophilia (AML-M4Eo) is often reported in core binding factor (CBF) leukemia, with translocations such as inv(16)(p13q22), t(16;16)(p13;q22) or t(8;21)(q22;q22); however, it is rarely reported with t(16;21)(q24;q22), which produces the RUNX1-CBFA2T3 (AML1-MTG16) chimera. The similarity between this chimera and RUNX1-RUNXT1 (AML1-MTG8) by t(8;21)(q22;q22) remains controversial. Adult leukemia with t(16;21)(q24;q22) was primarily therapy related, and shows poor prognosis; however, pediatric AML with this translocation was quite rare and tended to be de novo AML. We present here a 4-year-old boy with de novo AML-M4Eo and t(16;21)(q24;q22). He received chemotherapy and survived for more than 70 months without transplantation. We speculated that pediatric AML with t(16;21)(q24;q22) showed favorable prognosis, as with t(8;21)(q22;q22).

Indexed as

Antineoplastic AgentsBone MarrowChildChromosomes, Human, Pair 16Chromosomes, Human, Pair 21Core Binding Factor Alpha 2 SubunitEosinophiliaHumansLeukemia, Myeloid, AcuteMaleRepressor ProteinsTranslocation, GeneticTumor Suppressor ProteinsAntineoplastic AgentsCBFA2T3 protein, humanCore Binding Factor Alpha 2 SubunitRepressor ProteinsTumor Suppressor Proteins

Identifiers

PMID22403058
OpenAlexW2093301309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.